Twist Bioscience Corporation's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company gets cash to invest in growth by selling ownership stakes to investors through Goldman Sachs and other banks.
This official prospectus confirms details of the company's plan to raise capital through a public stock sale.
The preliminary prospectus shows the company's intent to raise capital when stock traded at $101.06 per share.
Quarterly earnings reports show how well a company performed and help investors decide if it's growing.
Quarterly earnings reports show how well a company performed and help investors decide if it's growing.
Quarterly earnings reports show how well a company performed and help investors decide if it's growing.
Stocky reads Twist Bioscience Corporation's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Twist Bioscience Corporation's most recent tracked filing was a 8-K on 5 Aug 2026: Raises $327 million selling 3.6 million shares at $96.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.